Integrated space-frequency-time domain feature extraction for MEG-based Alzheimer's disease classification.

Magnetoencephalography (MEG) has been combined with machine learning techniques, to recognize the Alzheimer's disease (AD), one of the most common forms of dementia. However, most of the previous studies are limited to binary classification and do not fully utilize the two available MEG modalities (extracted using magnetometer and gradiometer sensors). AD consists of several stages of progression, this study addresses this limitation by using both magnetometer and gradiometer data to discriminate between participants with AD, AD-related mild cognitive impairment (MCI), and healthy control (HC) participants in the form of a three-class classification problem. A series of wavelet-based biomarkers are developed and evaluated, which concurrently leverage the spatial, frequency and time domain characteristics of the signal. A bimodal recognition system based on an improved score-level fusion approach is proposed to reinforce interpretation of the brain activity captured by magnetometers and gradiometers. In this preliminary study, it was found that the markers derived from gradiometer tend to outperform the magnetometer-based markers. Interestingly, out of the total 10 regions of interest, left-frontal lobe demonstrates about 8% higher mean recognition rate than the second-best performing region (left temporal lobe) for AD/MCI/HC classification. Among the four types of markers proposed in this work, the spatial marker developed using wavelet coefficients provided the best recognition performance for the three-way classification. Overall, the proposed approach provides promising results for the potential of AD/MCI/HC three-way classification utilizing the bimodal MEG data.

Detection of Mild Cognitive Impairment with MEG Functional Connectivity Using Wavelet-Based Neuromarkers.

Studies on developing effective neuromarkers based on magnetoencephalographic (MEG) signals have been drawing increasing attention in the neuroscience community. This study explores the idea of using source-based magnitude-squared spectral coherence as a spatial indicator for effective regions of interest (ROIs) localization, subsequently discriminating the participants with mild cognitive impairment (MCI) from a group of age-matched healthy control (HC) elderly participants. We found that the cortical regions could be divided into two distinctive groups based on their coherence indices. Compared to HC, some ROIs showed increased connectivity (hyper-connected ROIs) for MCI participants, whereas the remaining ROIs demonstrated reduced connectivity (hypo-connected ROIs). Based on these findings, a series of wavelet-based source-level neuromarkers for MCI detection are proposed and explored, with respect to the two distinctive ROI groups. It was found that the neuromarkers extracted from the hyper-connected ROIs performed significantly better for MCI detection than those from the hypo-connected ROIs. The neuromarkers were classified using support vector machine (SVM) and k-NN classifiers and evaluated through Monte Carlo cross-validation. An average recognition rate of 93.83% was obtained using source-reconstructed signals from the hyper-connected ROI group. To better conform to clinical practice settings, a leave-one-out cross-validation (LOOCV) approach was also employed to ensure that the data for testing was from a participant that the classifier has never seen. Using LOOCV, we found the best average classification accuracy was reduced to 83.80% using the same set of neuromarkers obtained from the ROI group with functional hyper-connections. This performance surpassed the results reported using wavelet-based features by approximately 15%. Overall, our work suggests that (1) certain ROIs are particularly effective for MCI detection, especially when multi-resolution wavelet biomarkers are employed for such diagnosis; (2) there exists a significant performance difference in system evaluation between research-based experimental design and clinically accepted evaluation standards.

M/EEG-Based Bio-Markers to Predict the MCI and Alzheimer's Disease: A Review From the ML Perspective.

This paper reviews the state-of-the-art neuromarkers development for the prognosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The first part of this paper is devoted to reviewing the recently emerged machine learning (ML) algorithms based on electroencephalography (EEG) and magnetoencephalography (MEG) modalities. In particular, the methods are categorized by different types of neuromarkers. The second part of the review is dedicated to a series of investigations that further highlight the differences between these two modalities. First, several source reconstruction methods are reviewed and their source-level performances explored, followed by an objective comparison between EEG and MEG from multiple perspectives. Finally, a number of the most recent reports on classification of MCI/AD during resting state using EEG/MEG are documented to show the up-to-date performance for this well-recognized data collecting scenario. It is noticed that the MEG modality may be particularly effective in distinguishing between subjects with MCI and healthy controls, a high classification accuracy of more than 98% was reported recently; whereas the EEG seems to be performing well in classifying AD and healthy subjects, which also reached around 98% of the accuracy. A number of influential factors have also been raised and suggested for careful considerations while evaluating the ML-based diagnosis systems in the real-world scenarios.